View
212
Download
0
Tags:
Embed Size (px)
Citation preview
Region I Advisory Board MeetingWells Beach, ME
June 9, 2008
Use and Verification of STD Nucleic Acid Amplification Tests
for non-FDA Cleared Clinical Specimens
Presenter: Sally Liska, DrPHDirector, San Francisco PH Lab
“From Tommy Bahama [Levi Strauss] to LL Bean”
Background: San Francisco Public Health Laboratory
• Local PH Lab – support Communicable Disease programs (STD, HIV, TB, etc.)
• Methods – microbiology, virology, serology, molecular diagnostics
• Process > 100,000 specimens/yr from DPH clinics, specialty clinics,
jails, NGO clinics, “events”,
etc.
Hx of CT/GC Lab Testingat the SFDPH Lab
A. Culture for N. gonorrhoeae
B. Nucleic Acid Amplification (NAAT)• Ligase Chain Reaction {LCR} – Abbott; 1995• Strand Displacement Amplification {SDA} –
Becton Dickinson; 2001• Transcription Mediated Amplification
{TMA} – Gen-Probe; 2004 • Polymerase Chain Reaction
{PCR}
Monthly STD stats – SFDPH Lab
STD NAAT Testing by Source; April, 2008
N = 5,000
Cervical/ Vaginal 12 %
Urethral/ Urine 45 %
Rectal 20 %
Oropharyngeal 22 %
Why Test Rectal & OropharyngealSpecimens
• Reduce acquisition and transmission of STD agents (Chlamydia, Gonorrhea, HIV)
• Rectal infections can cause proctitis and increase risk of HIV infection
• CDC recommendations for MSM – GC: annual screening of anatomical
sites w/ possible exposure CT: annual screening for urethral and
rectal infection
NAAT’s vs. Culture – Pharyngeal Gonorrhea
LCR + LCR - TOTAL
Culture Positive
8 1 9
Culture Negative
14 177 191
TOTAL 22 178 200
Performance CharacteristicsPharyngeal Gonorrhea
Sensitivity Specificity
CULTURE 47.4 % 100 %
LCR 94.7 % 97.8 %
Page-Shafer et al in CID, 2002; 34:173-6
How Prevalent in Non-genital Sites?
Figure 1. City-specific median percent of visits where gonorrhea and chlamydia tests were performed and positivity among MSM, 2002-2006
72.5%
28.2%
43.4%
70.0%
5.1% 6.6%6.4% 4.3% 4.7%7.1%
1.1%
11.7%
0%
20%
40%
60%
80%
Urethral GC Rectal GC PharyngealGC
Urethral CT Rectal CT* PharyngealCT**
% o
f v
isit
s
Median Percent Tested
Median Positivity
Symptomatic vs. Asymptomatic Infection
0.5%
7.8%
6.7%
7.7%
1.0%
4.8%
9.2%
8.5%
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
Pre
vale
nce o
f In
fecti
on
Asymptomatic Symptomatic
What if we didn’t sample these sites?
CT (n = 574) GC (n = 785)
Identified 47 % 36 %
Non-identified 53 % 64 %
From Kent et al; CID 2005:41
What About Women?
When to do rectal & pharyngeal screening in women, what are the indicators?
1. HRSA recommends screening HIV + women (by culture)
2. Medical indications – risk of reinfection if not treated for (rectal) infection?
3. PH indications – prevalence for these sites in women largely unknown
Use of NAAT’s for R & Ph specimens
PRO’s• More sensitive than
culture• More universal than
CT culture• Faster turn around
time• Can be automated
CON’s• May be more
expensive• NAAT’s not approved
for these sites by FDA
Performance of NAATs on 1,110 Oropharyngeal Swab Specimens
TestTest Sensitivity (%)Sensitivity (%) Specificity (%)Specificity (%)
CT:CT:
CultureCulture 44.444.4 100100
AC2AC2 100100 99.899.8
SDASDA 66.766.7 100100
GC:GC:
CultureCulture 40.440.4 100100
AC2AC2 84.384.3 99.499.4
SDASDA 71.971.9 99.599.5
Performance of NAAT’s on 1,110 Rectal Swab Specimens
TestTest Sensitivity (%)Sensitivity (%) Specificity (%)Specificity (%)
CT:CT:
CultureCulture 26.526.5 100100
AC2AC2 92.692.6 99.699.6
SDASDA 63.263.2 100100
GC:GC:
CultureCulture 43.243.2 100100
AC2AC2 93.293.2 99.799.7
SDASDA 78.478.4 99.999.9
CLIA ’88
• Federal regulation w/ oversight on clinical labs – Dx, Rx & prevention of disease
• Section 493.1213 pertains to requirement for Verification of Method Performance for:– In-house developed method– Modification of a manufacturer’s procedure– Method not cleared by the FDA
Verification• A 1-time process completed before the test is
used for patient testing.
• Requires determination of the test performance characteristics – ▪ Sensitivity ▪ Reportable range
▪ Specificity ▪ Reference range
▪ Precision ▪ Other characteristics
▪ Accuracy required for test performance
From Cumitech 31; ASM press 1997
Verification Protocol• Purpose of test – e.g. screening for R GC
• Write an SOP – pre to post-analytical testing
• Procure specimens – – 20 Positive – 50 Negative
• Set acceptability criteria
• Statement of findings w/ regard to implementation – document!
Options
• Do a VERIFICATION of your NAAT
• Regionalize testing service
• Send specimens out to commercial lab
• Reimbursement - – MediCal will reimburse for testing multiple
sites
Acknowledgements• SFDPH
Diane Campbell, Leah Rauch & lab staff
Charlotte Kent, Dr. Jeff
Klausner & City Clinic
clinicians • UCSF
Julius Schachter & Jeanne Moncada
• CA STD Control
Drs. Gail Bolan & Chris Hall• CDC – Dr. John Papp• Manufacturers